Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Income from Continuing Operations (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Income from Continuing Operations for 6 consecutive years, with 11081000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 316.72% year-over-year to 11081000.0, compared with a TTM value of 554000.0 through Dec 2025, up 101.01%, and an annual FY2025 reading of 554000.0, up 101.01% over the prior year.
  • Income from Continuing Operations was 11081000.0 for Q4 2025 at Xeris Biopharma Holdings, up from 621000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 11081000.0 in Q4 2025 and bottomed at 50790000.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 16696100.0, with a median of 16286000.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations tumbled 132.37% in 2021, then soared 316.72% in 2025.
  • Year by year, Income from Continuing Operations stood at 50790000.0 in 2021, then soared by 74.54% to 12930000.0 in 2022, then dropped by 3.56% to 13390000.0 in 2023, then surged by 61.81% to 5113000.0 in 2024, then skyrocketed by 316.72% to 11081000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for XERS at 11081000.0 in Q4 2025, 621000.0 in Q3 2025, and 1928000.0 in Q2 2025.